Skip to main content

Search

Vaccines – the most powerful tool in healthcare?

Vaccines – the most powerful tool in healthcare?

Vaccines have transformed public health over the last 50 years. Smallpox has been eradicated and now polio, measles, and hepatitis B are being targeted for elimination. However, many infectious diseases are not yet under control. Developing new vaccines for them is a huge challenge. Researchers, clinicians and small and large biopharmaceutical companies have therefore launched the Flanders Vaccine consortium.

Vaccines are designed for healthy people, whereas medicines are used to treat sick people. Prevention is an important pillar of Janssen’s vision on healthcare. We’re working on vaccines and building on the extensive expertise of Crucell, a company which Janssen took over a few years ago.

The fight against Ebola

The Infectious Diseases & Vaccines therapeutic field is dedicated to finding solutions in the areas of prevention and treatment of all sorts of current infections such as influenza and RSV, hepatitis, HIV, and tuberculosis, but also dengue, Ebola, and polio. The Vaccines group led by Dr. Johan Van Hoof is currently working on the development of a preventive Ebola vaccine regimen. The recent Ebola crisis in some African countries has spurred many companies on to speed up their efforts to develop an Ebola vaccine, and J&J is also involved in this race against the clock.

Beyond infectious diseases

Vaccines are powerful weapons against infectious diseases, but Janssen is also researching further possibilities. One area of focus is prevention of diseases amongst the elderly, such as certain cancers, heart disease, and Alzheimer’s disease. At the start of 2015, the company launched the Janssen Prevention Center, a new Center of Excellence within Janssen Research and Development.

Janssen certainly wants to help shape Flanders Vaccine. It fits in perfectly with our corporate philosophy to promote the development of new healthcare solutions by working together and sharing ideas. We’re striving for a dynamic ecosystem where biopharmaceutical companies and universities collaborate to develop new preventive and therapeutic vaccines.